Apogee Therapeutics Secures Up to $1.3B Financing from Blackstone to Advance Zumilokibart

Shot: Apogee will receive ~$1.3B in flexible, non-dilutive capital from Blackstone, incl. ~$800M of synthetic royalty & ~$500M in senior debt available at the mutual consent of both parties, to support the late-stage development & potential commercialization of zumilokibart Blackstone will provide ~$800M in synthetic royalty funding to Apogee in exchange for 15-year tiered royalties…

ByRidhi RastogiMay 27, 2026

NEWS

Blackstone Closes $6.3B BXLS VI Fund, Making it the Largest Life Sciences Vehicle

Shots: Blackstone has closed Blackstone Life Sciences VI (BXLS VI) at its hard cap of $6.3B of total capital commitments, making it ~40% larger than its predecessor vehicle Blackstone launched BXLS platform in 2018, with ~$15B in assets under management as of Q4’25 & invests across the lifecycle of drugs and medtech, with an ~86%…

ByRidhi RastogiMarch 31, 2026

NEWS

Teva Lands $400M Blackstone Life Sciences Deal to Support Duvakitug Development

Shots: Teva & Blackstone Life Sciences have entered a four-year strategic funding agreement to support the continued clinical development of duvakitug As per the deal, Blackstone will provide $400M to Teva over four years to fund duvakitug development, while Blackstone will receive potential milestone payment subject to FDA approval, & additional commercial milestones, as well…

ByRidhi RastogiMarch 5, 2026

NEWS

Merck Signs an R&D Funding Deal with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Shots: Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences to support development of sac-TMT, currently in 15 global P-III trials across multiple cancers, including breast, endometrial, and lung As per the deal, Blackstone will provide Merck $700M to help fund sac-TMT development through 2026. In return, Blackstone is eligible for low-to-mid…

ByDipanshu DixitNovember 5, 2025

NEWS

Blackstone and TPG Acquire Hologic for ~ $18.3B

Shots: Hologic has agreed to be acquired by Blackstone and TPG for up to $79 per share, valuing the deal at up to $18.3B. The deal is expected to close in H1'26 As per the deal, Blackstone and TPG will acquire all Hologic shares for $76 per share in cash plus a non-tradable CVR worth…

ByDipanshu DixitOctober 21, 2025

NEWS

Elanco Inks a $295M Deal with Blackstone for Xdemvy’s Royalties and Milestones, Accelerating Debt Repayment

Shots: Elanco has sold certain future royalties & milestones linked to Xdemvy (0.25% lotilaner ophthalmic solution) for human use, to Blackstone Life Sciences & Blackstone Credit & Insurance to reduce its debt & strengthen its financial position As per the deal, Elanco will receive $295M in cash to repay portions of its loans on a…

ByRidhi RastogiMay 7, 2025

TOP 20

Top 20 Diagnostics Companies of 2026

Shots: The global diagnostics market is rapidly evolving through AI-powered imaging, molecular testing, precision medicine, and digital pathology solutions. In 2025, Siemens Healthineers led the industry with $20.54B in diagnostics revenue, followed by Roche at $17.52B and GE HealthCare at $17.49B, reflecting the growing adoption of advanced imaging, lab automation, and AI-driven diagnostics across global…

ByPrince GiriMay 29, 2026

NEWS

Apogee Therapeutics Reports Part B P-II (APEX) Data on Zumilokibart in Atopic Dermatitis (AD)

Shots: Part B of P-II (APEX) trial assessed high, medium, or low-dose zumilokibart vs PBO in 346 pts, where mid & high-doses met the 1EP at 16wks., with 61.6% pts on high dose, 65.9% on mid-dose & 50.5% on low dose achieved EASI-75 vs 23.4% on PBO At Wk. 16, mid-dose also met key 2EP…

ByRidhi RastogiMay 28, 2026

INSIGHTS+

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

Headlines, Trends, and the Signals Shaping the Future of Biopharma A Quarter That Reset the Biopharma Narrative The first quarter of 2026 did not simply continue the momentum of the global biopharmaceutical industry; it redefined its direction. From multi-billion-dollar acquisitions and accelerating rare disease breakthroughs to AI-powered discovery collaborations and gene therapy approvals, the industry demonstrated a clear shift toward precision innovation, strategic consolidation, and next-generation…

ByRidhi RastogiApril 1, 2026

NEWS

Hologic’s Aptima HPV Assay Receives the US FDA Approval for HPV Primary Screening

Shots: The US FDA has approved AptimaHPV Assay, an mRNA-based assay for clinician-collected HPV primary screening Approval follows completion of a real-world HPV screening study of 650,000+ women across US, showing the Aptima HPV Assay has clinically comparable sensitivity to an FDA-approved DNA-based HPV test & is effective for detecting CIN2+ & CIN3+ in primary…

ByRidhi RastogiFebruary 5, 2026

Apogee Therapeutics Secures Up to $1.3B Financing from Blackstone to Advance Zumilokibart

Blackstone Closes $6.3B BXLS VI Fund, Making it the Largest Life Sciences Vehicle

Teva Lands $400M Blackstone Life Sciences Deal to Support Duvakitug Development

Merck Signs an R&D Funding Deal with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Blackstone and TPG Acquire Hologic for ~ $18.3B

Elanco Inks a $295M Deal with Blackstone for Xdemvy’s Royalties and Milestones, Accelerating Debt Repayment

Top 20 Diagnostics Companies of 2026

Apogee Therapeutics Reports Part B P-II (APEX) Data on Zumilokibart in Atopic Dermatitis (AD)

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

Hologic’s Aptima HPV Assay Receives the US FDA Approval for HPV Primary Screening

Contact US

FOLLOW US